Saturday 17 October 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024. In the quarter to June 2026, revenue grew 3.50%, EPS grew 41.5% and free cash flow grew 4.40%, each against the same quarter a year earlier.
3.47
0.14
−3.88%
Follow PRME
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
148.77 | 111.44 | 152.77 | 160.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(25.38) | (13.86) | (14.43) | (15.93) | |
P/B ratio |
5.49 | 4.27 | 8.04 | 16.43 | |
Price to Tangible BV |
5.49 | 4.27 | 8.04 | 16.43 | |
EV/Sales |
113.08 | 73.08 | 119.19 | 137.22 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.20) | (2.08) | (3.07) | (3.58) | |
EV/FCF |
(5.87) | (2.03) | (3.03) | (3.56) | |
Quick Ratio |
6.09 | 4.74 | 3.73 | 3.00 | |
Current Ratio |
6.61 | 4.84 | 3.80 | 3.05 | |
Net Debt/EBITDA |
4.05 | 3.74 | 2.75 | 2.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.01 | 0.02 | |
Operating CF/Net income |
0.69 | 0.81 | 0.87 | 0.97 | |
Capex/Depreciation |
(0.19) | (0.27) | (0.15) | (0.03) | |
Research and Development Expense of Revenue |
3,591.02% | 4,141.89% | 3,984.23% | 2,894.02% | |
Selling, General and Administrative Expense of Revenue |
914.94% | 1,758.59% | 2,033.29% | 956.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,040.57% | 538.78% | 542.52% | 421.58% | |
Graham Net Nets |
0.01 | (0.08) | (0.13) | (0.17) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.99%) | (39.29%) | (35.73%) | (29.09%) | |
Free Cash Flow Yield |
(12.94%) | (32.37%) | (25.76%) | (23.98%) | |
Revenue per Share |
0.01 | 0.01 | 0.00 | 0.01 | |
Operating CF per Share |
(0.22) | (0.25) | (0.24) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.25) | (0.24) | (0.23) | |
Cash per Share |
1.33 | 1.19 | 0.77 | 0.54 | |
Shareholders Equity per Share |
1.01 | 0.81 | 0.43 | 0.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.01 | 0.81 | 0.43 | 0.22 | |
Free Cash Flow |
(35.29) | (37.55) | (42.92) | (41.09) | |
Working Capital |
196.39 | 143.85 | 101.60 | 65.11 | |
Capital Expenditures |
(0.25) | (0.29) | (0.21) | (0.05) | |
Net Current Asset Value |
8.22 | (40.57) | (80.14) | (112.43) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.20 | 0.35 | 0.25 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.39 | 10.12 | 11.18 | 6.09 | |
Average Assets |
358.90 | 320.12 | 311.45 | 264.02 | |
Average Common Equity |
175.66 | 137.01 | 91.81 | 50.33 |
Columns are period end dates